Physician profile
Laura Davidson
NPI 1881778561
$4,231.19
in general payments reported to CMS, 2019-2025
32 companies · $425 in 2025
The $425 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $60.67 · 2021: $589 · 2022: $980 · 2023: $722 · 2024: $1,026 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.86 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $427.79 | 2022-2025 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $406.84 | 2021-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $305.80 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $289.67 | 2021-2024 | |
| Myovant Sciences INC. | $285.06 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $239.93 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $206.60 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $149.64 | 2022-2024 | |
| Daiichi Sankyo INC. | $129.49 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.44 | 2019-2023 | |
| Millicent US INC | $124.61 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Shield Therapeutics INC | $120.89 | 2023-2024 | Accrufer |
| Agile Therapeutics, INC. | $101.57 | 2022-2024 | Twirla |
| Hologic Sales and Service, LLC | $100.47 | 2019-2024 | Aptima, Thinprep 2000 Processor |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $98.93 | 2019-2022 | |
| Avion Pharmaceuticals | $82.86 | 2020-2023 | Balcoltra |
| Merck Sharp & Dohme LLC | $59.92 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $56.99 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $56.93 | 2019 | |
| Allergan, INC. | $54.71 | 2019 | |
| Avanos Medical | $51.40 | 2019-2024 | On-Q* Pump and Accessories |
| Radius Health, INC. | $36.64 | 2024 | Tymlos |
| Duchesnay USA Incorporated | $34.11 | 2019 | |
| Lupin INC. | $33.60 | 2019 | |
| Vertical Pharmaceuticals, LLC | $28.06 | 2019 | |
| Coopersurgical, INC. | $27.46 | 2019-2021 | |
| Roche Diagnostics Corporation | $22.81 | 2019 | |
| Organon LLC | $20.66 | 2022 | |
| Smith+Nephew, INC. | $19.96 | 2024 | Pico 7 |
| Aspira Women'S Health INC | $17.40 | 2024 | Ova1 |
| Mission Pharmacal Company | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.